Browse by Journal Title

Article

Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial.
Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A.S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J., Greil, R., Feuring-Buske, M., Markova, J., Rüffer, J.U., Kobe, C., Eich, H.T., Baues, C., Fuchs, M., Borchmann, P. and Behringer, K.
Annals of Oncology 35 (3): 276-284. March 2024

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
Rohr, U.P., Herrmann, P., Ilm, K., Zhang, H., Lohmann, S., Reiser, A., Muranyi, A., Smith, J., Burock, S., Osterland, M., Leith, K., Singh, S., Brunhoeber, P., Bowermaster, R., Tie, J., Christie, M., Wong, H.L., Waring, P., Shanmugam, K., Gibbs, P. and Stein, U.
Annals of Oncology 28 (8): 1869-1875. 1 August 2017

SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study.
Sinn, M., Sinn, B.V., Striefler, J.K., Lindner, J.L., Stieler, J.M., Lohneis, P., Bischoff, S., Blaeker, H., Pelzer, U., Neuhaus, P., Dietel, M., Doerken, B., Oettle, H., Riess, H. and Denkert, C.
Annals of Oncology 25 (5): 1025-1032. May 2014

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.
Meyer, A.H., Stroux, A., Lerch, K., Eucker, J., Eitle, J., Hohloch, K., Andrzejak, M., Possinger, K., Dörken, B., Pezzutto, A. and Scholz, C.W.
Annals of Oncology 25 (1): 210-215. January 2014

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay, A.E., Klimm, B., Chen, B.E., Goergen, H., Shepherd, L.E., Fuchs, M., Gospodarowicz, M.K., Borchmann, P., Connors, J.M., Markova, J., Crump, M., Lohri, A., Winter, J.N., Doerken, B., Pearcey, R.G., Diehl, V., Horning, S.J., Eich, H.T., Engert, A. and Meyer, R.M.
Annals of Oncology 24 (12): 3065-3069. December 2013

Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort.
Schlesinger, S., Aleksandrova, K., Pischon, T., Jenab, M., Fedirko, V., Trepo, E., Overvad, K., Roswall, N., Tjønneland, A., Boutron-Ruault, M.C., Fagherazzi, G., Racine, A., Kaaks, R., Grote, V.A., Boeing, H., Trichopoulou, A., Pantzalis, M., Kritikou, M., Mattiello, A., Sieri, S., Sacerdote, C., Palli, D., Tumino, R., Peeters, P.H., Bueno-de-Mesquita, H.B., Weiderpass, E., Quirós, J.R., Zamora-Ros, R., Sánchez, M.J., Arriola, L., Ardanaz, E., Tormo, M.J., Nilsson, P., Lindkvist, B., Sund, M., Rolandsson, O., Khaw, K.T., Wareham, N., Travis, R.C., Riboli, E. and Nöthlings, U.
Annals of Oncology 24 (9): 2449-2455. September 2013

NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
Terwey, T.H., Le Duc, T.M., Hemmati, P.G., le Coutre, P., Nagy, M., Martus, P., Doerken, B. and Arnold, R.
Annals of Oncology 24 (5): 1363-1370. May 2013

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser, F., Seymour, J.F., Kluin-Nelemans, H.C., Grigg, A., Wolf, M., Pfreundschuh, M., Tilly, H., Raemaekers, J., van't Veer, M.B., Milpied, N., Cartron, G., Pezzutto, A., Spencer, A., Reyes, F. and Dreyling, M.
Annals of Oncology 19 (2): 247-253. February 2008

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Nickenig, C., Dreyling, M., Hoster, E., Ludwig, W.D., Doerken, B., Freund, M., Huber, C., Ganser, A., Truemper, L., Forstpointner, R., Unterhalt, M. and Hiddemann, W.
Annals of Oncology 18 (1): 136-142. January 2007

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sieniawski, M., Sieber, M., Kirchner, H.H., Doerken, B., Hossfeld, D.K., Kisro, J., Metzner, B., Berdel, W.E., Diehl, V. and Engert, A.
Annals of Oncology 16 : 116-123. 1 January 2005

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting, A., Sieniawski, M., Glossmann, J.P., Staak, O., Nogova, L., Peters, N., Mapara, M., Doerken, B., Ko, Y., Metzner, B., Kisro, J., Diehl, V. and Engert, A.
Annals of Oncology 16 : 1359-1365. 1 January 2005

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H.H., Doerken, B., Hossfeld, D.K., Diehl, V. and Engert, A.
Annals of Oncology 13 (10): 1628-1635. October 2002

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Harstrick, A., Kohne, C.H., Hiddemann, W., Preusser, P., Strumberg, D., Berns, T., Seeber, S., Wilke, H. and Schmoll, H.J.
Annals of Oncology 8 : 917-918. 1 September 1997

Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Streit, M., Jaehde, U., Stremetzne, S., Ridwelski, K., Kerz, H., Strohbach, F., Hohenberger, P., Zwiebel, F., Hebart, H., Boethig, R., Kairies, M., Zillig, D., Schuchmann, S., Warnecke, S., Thiel, E. and Kreuser, E.
Annals of Oncology 8 : 1163-1165. 1 January 1997

Detection and management of advanced gastric cancer.
Hohenberger, P. and Huenerbein, M.
Annals of Oncology 7 : 197-203. 1 January 1996

Interferon-alpha does not improve the antineoplastic efficacy of highdose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Koehne, C.H., Wilke, H., Hecker, H., Schoeffski, P., Kaeufer, C., Rauschecker, H., Andreesen, R., Ohl, U., Lange, H.J., Klaassen, U., Westerhausen, M., Hiddemann, W., Hennemann, B., Schott, G., Bade, J., Strohmeyer, G., Harstrick, A., Schubert, U., Bokemeyer, C. and Schmoll, H.J.
Annals of Oncology 6 : 461-466. 1 January 1995

Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Engelhard, M., Gerhartz, H., Brittinger, G., Engert, A., Fuchs, R., Geiseler, B., Gerhartz, D., Haunauske, A.R., Hartlapp, H.J., Huhn, D., Ludwig, W.D., Meusers, P., Mueller, P., Pees, H.W., Peschel, C., Radtke, H., Schadeck-Gressel, C., Schlimok, G., Siegert, W., Spann, W., Terhardt, E., Thiel, E., Wilmanns, W., Brandmaier, R., Ehrlich, H.J., Faerber, L., Parwaresch, M., Tiemann, M. and Lennert, K.
Annals of Oncology 5 Suppl. 2 : S 123-S 125. 1 January 1994

Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.
Koehne-Woempner, C., Schoeffski, P. and Schmoll, H.J.
Annals of Oncology 5 Suppl. 3 : 97-104. 1 January 1994

Dose-escalating induction chemotherapy supported by lenograstim proceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response andinvestigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
van Hoef, A.H.A.M., Baumann, I., Lange, C., Luft, T., De Wynter, E.A., Ranson, M., Morgenstern, G.R., Yvers, A., Dexter, T.M., Testa, N.G. and Howell, A.
Annals of Oncology 5 : 217-224. 1 January 1994